Home  |  Contact

Cellosaurus LC-2/ad (CVCL_1373)

[Text version]

Cell line name LC-2/ad
Synonyms LC-2-Ad; LC-2-ad; LC-2 ad; LC2/Ad; LC2/AD
Accession CVCL_1373
Resource Identification Initiative To cite this cell line use: LC-2/ad (RRID:CVCL_1373)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Doubling time: 58 hours, at 32th passage (PubMed=8291444).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations CCDC6-RET (RET/PTC1) gene fusion (PubMed=23578175).
EGFR p.Leu858Arg (c.2573T>G) (PubMed=16105816).
EGFR p.Glu746_Ala750del (PubMed=23154560).
Homozygous for TP53 p.Ser241Cys (c.722C>G) (Cosmic-CLP).
Genome ancestry Source: PubMed=30894373

Origin% genome
African3.51
Native American0.63
East Asian, North76.2
East Asian, South13.98
South Asian0.14
European, North0.91
European, South4.65
Disease Lung adenocarcinoma (NCIt: C3512)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 51Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; ECACC; RCB

Markers:
AmelogeninX
CSF1PO10,11
D5S81810
D7S82011
D13S31710,12
D16S5399
TH017
TPOX11
vWA16,19

Run an STR similarity search on this cell line
Publications

PubMed=8291444; DOI=10.1111/j.1440-1827.1993.tb03232.x
Kataoka H., Itoh H., Seguchi K., Koono M.
Establishment and characterization of a human lung adenocarcinoma cell line (LC-2/ad) producing alpha 1-antitrypsin in vitro.
Acta Pathol. Jpn. 43:566-573(1993)

PubMed=8348978; DOI=10.1016/0014-5793(93)80946-R
Kataoka H., Seguchi K., Inoue T., Koono M.
Properties of alpha 1-antitrypsin secreted by human adenocarcinoma cell lines.
FEBS Lett. 328:291-295(1993)

PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331
Nagai Y., Miyazawa H., Huqun X., Tanaka T., Udagawa K., Kato M., Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Cancer Res. 65:7276-7282(2005)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=22313637; DOI=10.4161/cbt.19238
Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A., Igishi T., Burioka N., Nanba E., Shimizu E.
Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
Cancer Biol. Ther. 13:369-378(2012)

PubMed=23154560; DOI=10.1097/JTO.0b013e3182721ed1
Matsubara D., Kanai Y., Ishikawa S., Ohara S., Yoshimoto T., Sakatani T., Oguni S., Tamura T., Kataoka H., Endo S., Murakami Y., Aburatani H., Fukayama M., Niki T.
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
J. Thorac. Oncol. 7:1872-1876(2012)

PubMed=23578175; DOI=10.1111/cas.12175
Suzuki M., Makinoshima H., Matsumoto S., Suzuki A., Mimaki S., Matsushima K., Yoh K., Goto K., Suzuki Y., Ishii G., Ochiai A., Tsuta K., Shibata T., Kohno T., Esumi H., Tsuchihara K.
Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.
Cancer Sci. 104:896-903(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

Cross-references
Cell line collections ECACC; 94072247
RCB; RCB0440
Cell line databases/resources CCLE; LC2AD_LUNG
Cell_Model_Passport; SIDM00297
Cosmic-CLP; 907786
DepMap; ACH-002157
LINCS_LDP; LCL-1667
Ontologies CLO; CLO_0050073
EFO; EFO_0003140
Biological sample resources BioSample; SAMN03472314
Chemistry resources ChEMBL-Cells; CHEMBL3308545
ChEMBL-Targets; CHEMBL2366260
GDSC; 907786
PharmacoDB; LC2ad_831_2019
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM1670043
Other Wikidata; Q54902124
Polymorphism and mutation databases Cosmic; 907786
Cosmic; 946052
Cosmic; 1154602
Cosmic; 1571726
Cosmic; 1656903
Cosmic; 1995480
IARC_TP53; 21470
Entry history
Entry creation04-Apr-2012
Last entry updated06-Sep-2019
Version number23